Navigation Links
YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
Date:5/27/2010

ctively target cancer cells resulting in improvements to the safety profiles of antibodies and the consequent prospect of their conjugation to highly potent toxins for safe delivery to tumour tissue. YM is also developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communic
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
2. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
3. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
4. YM BioSciences third quarter 2010 operational and financial results
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
7. YM BioSciences announces controlled equity offering
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
9. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
10. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
11. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... devices with unprecedented efficiency and data storage ... use built-in electric polarizations to read and ... most popular data-driven technology. But ferroelectrics must ... including a curious habit of "forgetting" stored ... U.S. Department of Energy,s Brookhaven National Laboratory ...
(Date:8/18/2014)... , August 18, 2014 ... Bioreactor Systems Market, By Application (Municipal Wastewater Treatment ... Flat Sheet and Multi Tubular), By Configuration (Internal/Submerged ... 2019", published by MarketsandMarkets, The market for membrane ... by 2019, growing at a CAGR of 15.28% ...
(Date:8/18/2014)... August 18, 2014 China is ... for the clinical research industry. Clinicaltrial.gov statistics highlight ... to its aging population; a high increase in ... a densely populated pool of patients and a ... these positive points, China also presents challenges for ...
(Date:8/16/2014)... $229,214 grant from the Walmart Foundation to build a ... cut the manufacturing costs of goods, allowing those goods ... formerly built overseas. , The Walmart U.S. Manufacturing Innovation ... in awards to seven research and development institutions at ... through the collaboration between Walmart, the U.S. Conference of ...
Breaking Biology Technology:Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2UT Arlington receives Walmart, Walmart Foundation innovation grant 2UT Arlington receives Walmart, Walmart Foundation innovation grant 3
... Inc. (Amex:,SGN) has received its second Frost & Sullivan ... 2008, at the Frost & Sullivan Awards Banquet,Signalife was ... American Patient Monitoring. Signalife,s Chief Executive Officer, Dr.,Lowell Harmison, ... present to accept the award., Signalife, Inc. is ...
... result in longer-lasting, safer batteries for ... cars, ... Department of Energy,s,(DOE) Argonne National Laboratory and Toda Kogyo Corp. ... commercial production and,sales of Argonne,s patented composite cathode materials for ...
... March 13 Arpida Ltd,(SWX: ARPN) announced today its ... 2007 highlights, Major pipeline progress:, - Second ... its pre-specified primary endpoint, as did the first, ... iclaprim in,cSSSI initiated, - First patients enrolled in ...
Cached Biology Technology:Signalife Wins Second Frost & Sullivan Technology Award 2Signalife Wins Second Frost & Sullivan Technology Award 3Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 2Argonne's Lithium-Ion Battery Technology to be Commercialized by Japan's Toda Kogyo 3Arpida Announces Full Year 2007 Financial Results 2Arpida Announces Full Year 2007 Financial Results 3Arpida Announces Full Year 2007 Financial Results 4Arpida Announces Full Year 2007 Financial Results 5Arpida Announces Full Year 2007 Financial Results 6Arpida Announces Full Year 2007 Financial Results 7Arpida Announces Full Year 2007 Financial Results 8Arpida Announces Full Year 2007 Financial Results 9
(Date:8/19/2014)... A team of UTSA researchers has been awarded a ... Technology and Training (NCPTT), an office of the National ... The grant will fund a one-year study of the ... of historic homes in hot, humid climates. , Radiant ... or attics that reflect heat back, thereby reducing the ...
(Date:8/19/2014)... 19, 2014A new ovoid structure discovered in the Nakhla ... a variety of minerals, and shows evidence of undergoing ... of the permafrost and mixing of surface and subsurface ... of analytical studies to determine the origin of this ... this ovoid formed, point to the most likely conclusion, ...
(Date:8/19/2014)... concentrations of African dust transported to South America ... These research findings offer new insight on the ... African dust, including the climate change-induced human health ... African dust emissions in the coming decades., Researchers ... of Marine and Atmospheric Science and colleagues analyzed ...
Breaking Biology News(10 mins):UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3Life on Mars? Implications of a newly discovered mineral-rich structure 2Study of African dust transport to South America reveals air quality impacts 2
... historical water conditions. By synthesizing present-day data with ... trends on a regional basis for periods from which scant ... impede hydrologists, understanding of the current state of waterways and ... was the case for the rivers of the northeastern United ...
... to measure the structure of membrane proteins despite being damaged ... help fast track the development of targeted drugs using emerging ... today depend on the activity of membrane proteins, which are ... our body. A major problem for the design of ...
... crow, a forest crow living on Rota Island in the ... The extinction could happen almost twice as soon as previously ... bird management program that focuses on helping fledgling birds reach ... in psychology. Ha examined survival rates in 97 Mariana ...
Cached Biology News:CCNY-led interdisciplinary team recreates colonial hydrology 2CCNY-led interdisciplinary team recreates colonial hydrology 3Despite damage, membrane protein structure can be seen using new X-ray technology, study reveals 2Without intervention, Mariana crow to become extinct in 75 years 2
... allows for rapid, convenient, and efficient native ... process utilizes a spin column to make ... concentration of proteins which were electro-eluted in ... ion exchangers, offering high binding capacity fo ...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
Automated Cell Culture Flask...
... system, 100-240 V, is an optional module ... automates delivery of up to 20 L ... reader. The HTF system automatically draws sheath ... to constantly maintain a reservoir of pressurized ...
Biology Products: